These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 16564690

  • 21. Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate.
    Ogawa Y, Kawamura T, Furuhashi M, Tsukamoto K, Shimada S.
    J Dermatol Sci; 2008 Sep; 51(3):190-9. PubMed ID: 18485676
    [Abstract] [Full Text] [Related]

  • 22. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.
    Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A, Slavin S, Israel Glivec in Solid Tumors Study Group.
    Endocr Relat Cancer; 2006 Jun; 13(2):535-40. PubMed ID: 16728580
    [Abstract] [Full Text] [Related]

  • 23. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures.
    Hägerstrand D, Hesselager G, Achterberg S, Wickenberg Bolin U, Kowanetz M, Kastemar M, Heldin CH, Isaksson A, Nistér M, Ostman A.
    Oncogene; 2006 Aug 10; 25(35):4913-22. PubMed ID: 16547494
    [Abstract] [Full Text] [Related]

  • 24. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
    Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, Maass N, Mundhenke C.
    Cancer Lett; 2009 Jan 08; 273(1):70-9. PubMed ID: 18809244
    [Abstract] [Full Text] [Related]

  • 25. Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis.
    Lozano E, Segarra M, García-Martínez A, Hernández-Rodríguez J, Cid MC.
    Ann Rheum Dis; 2008 Nov 08; 67(11):1581-8. PubMed ID: 17584806
    [Abstract] [Full Text] [Related]

  • 26. Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts.
    Sandler C, Joutsiniemi S, Lindstedt KA, Juutilainen T, Kovanen PT, Eklund KK.
    Biochem Biophys Res Commun; 2006 Aug 18; 347(1):31-5. PubMed ID: 16806061
    [Abstract] [Full Text] [Related]

  • 27. Basis for dosing time-dependent change in the anti-tumor effect of imatinib in mice.
    Nakagawa H, Takiguchi T, Nakamura M, Furuyama A, Koyanagi S, Aramaki H, Higuchi S, Ohdo S.
    Biochem Pharmacol; 2006 Nov 15; 72(10):1237-45. PubMed ID: 16973134
    [Abstract] [Full Text] [Related]

  • 28. Enhancement of radiation sensitivity, delay of proliferative recovery after radiation and abrogation of MAPK (p44/42) signaling by imatinib in glioblastoma cells.
    Quick QA, Gewirtz DA.
    Int J Oncol; 2006 Aug 15; 29(2):407-12. PubMed ID: 16820883
    [Abstract] [Full Text] [Related]

  • 29. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J, Lopez JP, Altuna X, Chu TS, Weisman RA, Ongkeko WM.
    Laryngoscope; 2006 Aug 15; 116(8):1409-16. PubMed ID: 16885745
    [Abstract] [Full Text] [Related]

  • 30. Chimeric tyrosine kinase-HDAC inhibitors as antiproliferative agents.
    Uecker A, Sicker M, Beckers T, Mahboobi S, Hägerstrand D, Ostman A, Böhmer FD.
    Anticancer Drugs; 2010 Sep 15; 21(8):759-65. PubMed ID: 20613486
    [Abstract] [Full Text] [Related]

  • 31. Correlation between 99mTc-(V)-DMSA uptake and constitutive level of phosphorylated focal adhesion kinase in an in vitro model of cancer cell lines.
    Denoyer D, Perek N, Le Jeune N, Cornillon J, Dubois F.
    Eur J Nucl Med Mol Imaging; 2005 Jul 15; 32(7):820-7. PubMed ID: 15785954
    [Abstract] [Full Text] [Related]

  • 32. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
    Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, Gonzalez C, Prieto VG.
    J Cutan Pathol; 2006 Apr 15; 33(4):280-5. PubMed ID: 16630177
    [Abstract] [Full Text] [Related]

  • 33. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).
    Mukherjee J, Kamnasaran D, Balasubramaniam A, Radovanovic I, Zadeh G, Kiehl TR, Guha A.
    Cancer Res; 2009 Jun 15; 69(12):5099-107. PubMed ID: 19509233
    [Abstract] [Full Text] [Related]

  • 34. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I, Akisue T, Hara H, Fujimoto T, Imabori M, Doita M, Kuroda R, Fujioka H, Kawamoto T, Yamamoto T, Kurosaka M.
    Anticancer Res; 2007 Jun 15; 27(1A):423-9. PubMed ID: 17352263
    [Abstract] [Full Text] [Related]

  • 35. Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth.
    Benny O, Menon LG, Ariel G, Goren E, Kim SK, Stewman C, Black PM, Carroll RS, Machluf M.
    Clin Cancer Res; 2009 Feb 15; 15(4):1222-31. PubMed ID: 19190128
    [Abstract] [Full Text] [Related]

  • 36. Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts.
    Gioni V, Karampinas T, Voutsinas G, Roussidis AE, Papadopoulos S, Karamanos NK, Kletsas D.
    Mol Cancer Res; 2008 May 15; 6(5):706-14. PubMed ID: 18505916
    [Abstract] [Full Text] [Related]

  • 37. Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis.
    Leipner C, Grün K, Müller A, Buchdunger E, Borsi L, Kosmehl H, Berndt A, Janik T, Uecker A, Kiehntopf M, Böhmer FD.
    Cardiovasc Res; 2008 Jul 01; 79(1):118-26. PubMed ID: 18326555
    [Abstract] [Full Text] [Related]

  • 38. Influence of imatinib mesylate on radiosensitivity of astrocytoma cells.
    Ranza E, Bertolotti A, Facoetti A, Mariotti L, Pasi F, Ottolenghi A, Nano R.
    Anticancer Res; 2009 Nov 01; 29(11):4575-8. PubMed ID: 20032406
    [Abstract] [Full Text] [Related]

  • 39. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study.
    Soria A, Cario-André M, Lepreux S, Rezvani HR, Pasquet JM, Pain C, Schaeverbeke T, Mahon FX, Taïeb A.
    Dermatology; 2008 Nov 01; 216(2):109-17. PubMed ID: 18216472
    [Abstract] [Full Text] [Related]

  • 40. Evidence that 99mTc-(V)-DMSA uptake is mediated by NaPi cotransporter type III in tumour cell lines.
    Denoyer D, Perek N, Le Jeune N, Frere D, Dubois F.
    Eur J Nucl Med Mol Imaging; 2004 Jan 01; 31(1):77-84. PubMed ID: 14557898
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.